Medimmune Limited

Simon Dovedi

Michelle Morrow

Changshou Gao

Scott A Hammond

Claire Louise Dobson

Ronald Herbst

Godfrey Rainey

Darren Schofield

Stacey Drabic

Yariv Mazor

Srinath Kasturirangan

Brian Lobo

Michael Oberst

Prakash Manikwar

Gianluca Carlesso

Jonathan Seaman

Kristen Pollizzi

Ross Anthony Stewart

Edmund Poon

Robert Wilkinson

Tim Illidge

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.

Bispecific binding proteins and uses thereof

This application provides a method of treating cancer in a patient comprising administering at least one dose of radiation therapy and at least one PD-1 and/or PD-L1 antagonist, wherein at least one PD-1 and/or PD-L1 antagonist is administered on the same day as a dose of radiation therapy or up to and including 4 days later.

Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy

Growing community of inventors

Cambridge, United Kingdom

Simon Dovedi